美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CRL近 30 天 20 則 · 第 1 / 1 頁
- Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch?
- PGNY vs. CRL: Which Stock Is the Better Value Option?
- What Is Charles River Laboratories International (CRL) Signaling With Its Faster Cell Banking Platform?
- Charles River Laboratories International (CRL) Stock Fair Value Rises After Analysts Lift Targets
- What Charles River Laboratories International (CRL)'s Accelerated, NGS-Enabled Cell Banking Platform Means For Shareholders
- Why Charles River Laboratories (CRL) Stock Is Trading Up Today
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- 3 Reasons to Sell CRL and 1 Stock to Buy Instead
- Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus
- Are Medical Stocks Lagging Amgen (AMGN) This Year?
- Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
- Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
- Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
- Here's Why You Should Hold Charles River Stock in Your Portfolio Now
- Is This the Right Time to Add CRL Stock to Your Portfolio?
- Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific
- Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
- Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
- 3 Inflated Stocks We Approach with Caution
- Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
- Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。